Skip to main content
Premium Trial:

Request an Annual Quote

Zymera Licenses Life Technologies' Qdot Technology

NEW YORK (GenomeWeb News) – Life Technologies said today that Zymera has licensed its quantum dot intellectual property portfolio.

Zymera plans to use the Qdot nanocrystals to create self-illuminating quantum dot products that will be used in in vivo imaging, biomarker discovery, and in biosensing applications. Zymera's self-illumination technology uses bioluminescence resonance energy transfer, to transfer light from bioluminescent proteins, such as luciferase, onto quantum dots.

The Qdot nanocrystals, which emit bright light when exposed to ultraviolet light, are used in disease studies and for detecting targets in complex mixtures.

Financial terms of the agreement were not released.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.